Managing Tardive Dyskinesia with VMAT2 Inhibitors

Understanding the Condition and Treatment

The American Psychiatric Association recommends VMAT2 inhibitors (valbenazine or deutetrabenazine) as first-line pharmacotherapy for moderate to severe or disabling tardive dyskinesia 1
Medicaid typically requires specialist evaluation and documentation before approving VMAT2 inhibitors for tardive dyskinesia 1

Reduce the dose of the current antipsychotics if clinically feasible, as lower doses may decrease tardive dyskinesia severity while maintaining psychiatric stability 1, 2
Switch to atypical antipsychotics with lower D2 affinity (such as quetiapine or clozapine) if the patient is on typical antipsychotics or high-potency atypicals 1, 2
Atypical antipsychotics have significantly lower risk of causing or worsening extrapyramidal symptoms compared to typical antipsychotics 2

Document the clinical necessity for antipsychotic polypharmacy, as it increases side effect burden 3, 4
Consider whether clozapine monotherapy could replace the two-antipsychotic regimen, as clozapine is underutilized and may provide better efficacy with lower tardive dyskinesia risk 4
If polypharmacy must continue, select antipsychotics with differing side-effect profiles to minimize cumulative dopaminergic blockade 3

Do not use anticholinergic medications (such as benztropine or trihexyphenidyl) for tardive dyskinesia—these are indicated for acute dystonia and parkinsonism, not tardive dyskinesia, and may worsen the condition 1

Prepare baseline and serial Abnormal Involuntary Movement Scale (AIMS) scores documenting severity 1, 2
Document that tardive dyskinesia is moderate to severe or disabling 1
Provide evidence that dose reduction or medication switching has been attempted or is not feasible due to psychiatric instability 1, 2
Justify continued antipsychotic use (i.e., why discontinuation is not an option) 1, 2